[go: up one dir, main page]

MX2019003241A - Moleculas de union que modulan una actividad biologica expresada por una celula. - Google Patents

Moleculas de union que modulan una actividad biologica expresada por una celula.

Info

Publication number
MX2019003241A
MX2019003241A MX2019003241A MX2019003241A MX2019003241A MX 2019003241 A MX2019003241 A MX 2019003241A MX 2019003241 A MX2019003241 A MX 2019003241A MX 2019003241 A MX2019003241 A MX 2019003241A MX 2019003241 A MX2019003241 A MX 2019003241A
Authority
MX
Mexico
Prior art keywords
cell
binding molecules
modulate
biological activity
activity expressed
Prior art date
Application number
MX2019003241A
Other languages
English (en)
Inventor
Throsby Mark
Anna Wilhelmina Geuijen Cecilia
Adriaan De Kruif Cornelis
Logtenberg Ton
Klooster Rinse
Johannes Tacken Paulus
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MX2019003241A publication Critical patent/MX2019003241A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona medios y métodos para estimular la actividad de un miembro de la superfamilia de receptores del TNF en una célula. La invención proporciona, además, moléculas de unión tales como anticuerpos que comprenden al menos dos parátopos, en donde un primer parátopo puede unir una parte extracelular del miembro y un segundo parátopo puede unir una parte extracelular de una segunda proteína de membrana (diferente).
MX2019003241A 2016-09-23 2017-09-22 Moleculas de union que modulan una actividad biologica expresada por una celula. MX2019003241A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16190499 2016-09-23
PCT/NL2017/050634 WO2018056821A1 (en) 2016-09-23 2017-09-22 Binding molecules that modulate a biological activity expressed by a cell

Publications (1)

Publication Number Publication Date
MX2019003241A true MX2019003241A (es) 2019-11-12

Family

ID=57132987

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003241A MX2019003241A (es) 2016-09-23 2017-09-22 Moleculas de union que modulan una actividad biologica expresada por una celula.

Country Status (19)

Country Link
US (2) US11685786B2 (es)
EP (2) EP4342912A3 (es)
JP (3) JP7305538B2 (es)
KR (2) KR20190065318A (es)
CN (2) CN117510643A (es)
AU (3) AU2017332452B2 (es)
BR (1) BR112019005895A2 (es)
CA (1) CA3038020A1 (es)
EA (1) EA201990578A1 (es)
ES (1) ES2981272T3 (es)
IL (2) IL265541B2 (es)
MA (1) MA46278A (es)
MX (1) MX2019003241A (es)
NZ (1) NZ751956A (es)
PH (1) PH12019550044A1 (es)
TW (1) TWI879715B (es)
UA (1) UA127449C2 (es)
WO (1) WO2018056821A1 (es)
ZA (1) ZA201902146B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2972990A1 (en) 2015-01-20 2016-07-28 Beatrice Tien-Yi WANG Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
CN109563171B (zh) 2016-06-20 2023-09-19 F-星治疗有限公司 结合pd-l1和lag-3的结合分子
US11214618B2 (en) 2016-06-20 2022-01-04 F-Star Therapeutics Limited LAG-3 binding members
MX2018015853A (es) 2016-07-14 2019-08-21 Genmab As Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
EP4342912A3 (en) 2016-09-23 2024-05-22 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
BR112020000228A2 (pt) 2017-07-06 2020-07-14 Merus N.V. anticorpos que modulam uma atividade biológica expressa por célula
AU2018309339C1 (en) 2017-08-04 2025-08-21 BioNTech SE Binding agents binding to PD-L1 and CD137 and use thereof
JP7489316B2 (ja) 2017-12-19 2024-05-23 エフ－スター セラピューティクス リミテッド Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片
EP3774919A4 (en) 2018-03-30 2021-12-29 Eureka Therapeutics, Inc. Constructs targeting cd22 and uses thereof
BR112020019795A2 (pt) * 2018-03-30 2021-01-05 Merus N.V. Anticorpo multivalente
US11993655B2 (en) 2018-04-09 2024-05-28 Oricell Therapeutics Co., Ltd. Anti-PD-L1 antibody and use thereof
CN112351998B (zh) * 2018-06-29 2022-07-22 苏州智核生物医药科技有限公司 Pd-l1结合多肽及其用途
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
IL280002B2 (en) 2018-07-12 2025-05-01 F Star Beta Ltd Antibody molecules that bind CD137 and OX40
TWI861005B (zh) * 2018-07-12 2024-11-11 英商英沃克斯製藥有限公司 結合pd-l1及cd137的抗體分子
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
TWI839395B (zh) * 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
EP3636320A1 (en) * 2018-10-09 2020-04-15 Numab Therapeutics AG Antibodies targeting cd137 and methods of use thereof
CN120983617A (zh) * 2018-11-06 2025-11-21 健玛保 抗体配制剂
KR20220008306A (ko) * 2019-05-10 2022-01-20 리브젠 바이오파마 코., 엘티디. 인간화 항-cd137 항체 및 이의 용도
US11725058B2 (en) * 2019-06-26 2023-08-15 Ap Biosciences, Inc. CD137 antibodies for T-cell activation
CN114555638B (zh) * 2019-10-11 2023-08-22 南京维立志博生物科技有限公司 结合4-1bb的抗体及其用途
EP4100059A1 (en) * 2020-02-04 2022-12-14 Genmab A/S Antibodies for use in therapy
CN115279403A (zh) 2020-02-21 2022-11-01 宏观基因有限公司 Cd137结合分子及其用途
US20230172189A1 (en) * 2020-04-28 2023-06-08 Ohio University Methods for Extending the Shelf-life of Stored Donor Blood and/or Red Blood Cells and Treated Red Blood Cell Compositions Produced Thereby
AU2021274522B2 (en) 2020-05-21 2025-10-09 Merus N.V. Methods and means for the production of Ig-like molecules
IL300225A (en) * 2020-07-31 2023-03-01 Chugai Pharmaceutical Co Ltd A pharmaceutical composition including chimeric receptor expressing cells
CN113416249B (zh) * 2020-10-21 2023-04-07 北京智仁美博生物科技有限公司 针对破伤风毒素的组合物
US20240052050A1 (en) * 2020-12-16 2024-02-15 Merus N.V. Multispecific antibodies for the treatment of cancer
IL304295B2 (en) * 2021-01-08 2025-07-01 Beijing Hanmi Pharmaceutical Co Ltd Anti-pd-l1/anti-4-1bb natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof
AU2022251985A1 (en) 2021-03-31 2023-10-19 Merus N.V. Novel multispecific antibodies
CN119868536A (zh) 2022-01-25 2025-04-25 美勒斯公司 用于治疗癌症的组合疗法
JP2025519057A (ja) * 2022-05-18 2025-06-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃｄ３８及び４－１ｂｂに結合する多重特異性抗原結合分子、並びにその使用
WO2025012620A1 (en) 2023-07-07 2025-01-16 Mestag Therapeutics Ltd Binding constructs

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
EP1975182A1 (en) * 2000-02-01 2008-10-01 PanGenetics B.V. CD40-binding APC-activating molecules
CN105884893A (zh) 2002-07-18 2016-08-24 莫鲁斯有限公司 抗体混合物的重组生产
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2006091209A2 (en) * 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
KR20110008086A (ko) 2008-04-11 2011-01-25 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
PL3456190T3 (pl) 2008-06-27 2022-06-06 Merus N.V. Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
AR075896A1 (es) 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
KR20130087517A (ko) 2010-06-25 2013-08-06 백시바디 에이에스 동종이합체 단백질 구조물
CA2810359C (en) 2010-09-09 2021-06-22 Pfizer Inc. 4-1bb binding molecules
PT2838917T (pt) 2012-04-20 2019-09-12 Merus Nv Métodos e meios para a produção de moléculas similares a ig heterodiméricas
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
CN107252485A (zh) 2013-04-03 2017-10-17 Ibc药品公司 用于诱导对疾病的免疫应答的组合疗法
MY176522A (en) * 2013-11-04 2020-08-13 Ichnos Sciences SA Production of t cell retargeting hetero-dimeric immunoglobulins
BR112016013963A2 (pt) * 2013-12-17 2017-10-10 Genentech Inc terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1
US10899840B2 (en) 2014-02-04 2021-01-26 Pfizer Inc. Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
CA2943943C (en) * 2014-04-07 2023-01-10 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
US20150307620A1 (en) * 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
CN117843799A (zh) * 2015-01-08 2024-04-09 生物技术公司 激动性tnf受体结合剂
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
AU2016206707A1 (en) * 2015-01-14 2017-08-10 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
EP3268037B1 (en) * 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
KR20180002653A (ko) 2015-04-07 2018-01-08 제넨테크, 인크. 효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법
CN107709367A (zh) * 2015-05-21 2018-02-16 鳄鱼生物科学公司 新型多肽
UY36687A (es) * 2015-05-29 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos contra ox40 y sus usos
DK3313876T3 (da) * 2015-06-23 2025-04-22 Innate Pharma Multispecifikke antigenbindende proteiner
KR20180053674A (ko) * 2015-10-02 2018-05-23 에프. 호프만-라 로슈 아게 공자극 tnf 수용체에 특이적인 이중특이성 항체
EP3359568B1 (en) 2015-10-07 2022-03-09 F. Hoffmann-La Roche AG Bispecific antibodies with tetravalency for a costimulatory tnf receptor
IL299072A (en) * 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods of use thereof
US20170198051A1 (en) * 2016-01-11 2017-07-13 Inhibrx Lp Multivalent and multispecific ox40-binding fusion proteins
SG10201912405TA (en) * 2016-01-11 2020-02-27 Inhibrx Inc Multivalent and multispecific 41bb-binding fusion proteins
AU2017252233A1 (en) * 2016-04-22 2018-11-15 Alligator Bioscience Ab Novel bispecific polypeptides against CD137
AR108377A1 (es) * 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
CA3025345A1 (en) 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP4342912A3 (en) 2016-09-23 2024-05-22 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
CN110305210B (zh) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途

Also Published As

Publication number Publication date
CA3038020A1 (en) 2018-03-29
TW201920653A (zh) 2019-06-01
WO2018056821A1 (en) 2018-03-29
AU2017332452A1 (en) 2019-04-11
AU2024220074A1 (en) 2024-10-17
EP4342912A3 (en) 2024-05-22
AU2021202085B2 (en) 2024-07-11
EP4342912A2 (en) 2024-03-27
JP7305538B2 (ja) 2023-07-10
BR112019005895A2 (pt) 2019-06-11
JP2019537429A (ja) 2019-12-26
UA127449C2 (uk) 2023-08-30
IL265541B2 (en) 2024-08-01
EP3515951B1 (en) 2024-02-28
US11685786B2 (en) 2023-06-27
EP3515951A1 (en) 2019-07-31
IL265541A (en) 2019-05-30
ZA201902146B (en) 2024-08-28
ES2981272T3 (es) 2024-10-08
JP2023116811A (ja) 2023-08-22
CN109983033B (zh) 2023-10-31
US20240209105A1 (en) 2024-06-27
IL265541B1 (en) 2024-04-01
NZ751956A (en) 2022-01-28
PH12019550044A1 (en) 2019-11-11
IL311603A (en) 2024-05-01
TWI879715B (zh) 2025-04-11
JP2025139596A (ja) 2025-09-26
CN109983033A (zh) 2019-07-05
AU2017332452B2 (en) 2021-01-07
EA201990578A1 (ru) 2019-10-31
WO2018056821A8 (en) 2019-05-02
CN117510643A (zh) 2024-02-06
AU2021202085A1 (en) 2021-04-29
KR20190065318A (ko) 2019-06-11
US20200017595A1 (en) 2020-01-16
KR20250007013A (ko) 2025-01-13
IL311603B1 (en) 2025-10-01
MA46278A (fr) 2019-07-31

Similar Documents

Publication Publication Date Title
ZA201902146B (en) Binding molecules that modulate a biological activity expressed by a cell
ZA202211577B (en) Multivalent and multispecific 41bb-binding fusion proteins
MY198560A (en) Bispecific antibodies specific for a costimulatory tnf receptor
JOP20210076A1 (ar) تركيبات أجسام مضادة ثنائية الاختصاص لربط خلايا تائية
AU2018258045A1 (en) Chimeric antibody/T-cell receptor constructs and uses thereof
EA202192165A1 (ru) Иммуноглобулины, связывающие человеческие v9v2 т-клеточные рецепторы
WO2016179518A3 (en) Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
PH12017501372A1 (en) Tnfrsf-binding agents and uses thereof
MX2024004017A (es) Proteinas de fusion de union a ox40 multivalentes y multiespecificas.
MX2021009852A (es) Anticuerpos humanos para pd-1.
BR112018008442A2 (pt) receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados
MX2018000948A (es) Proteinas de fusion que se unen a gitir multivalentes y multiespecificas.
PH12018500663A1 (en) Antigen-binding proteins that activate the leptin receptor
EA201891066A1 (ru) Антитела к ror1
WO2019105468A8 (en) Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody
EP4249066A3 (en) Antibodies to tigit
MX391388B (es) Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf.
MX2014014951A (es) Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
EA201892440A1 (ru) Антитела к tl1a и их применения
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
MX2020003503A (es) Proteinas de union al antigeno del receptor de oncostatina m.
PH12019501319A1 (en) Gremlin-1 crystal structure and inhibitory antibody
MX2020005364A (es) Anticuerpos anti-ox40 y usos de los mismos.
PH12019501605A1 (en) Glucagon receptor binding proteins and methods of use thereof
EA201790314A1 (ru) Новые антитела, направленные на fc-гамма-рецептор iib и fc-эпсилон-рецептор